BioNTech (NASDAQ:BNTX) Coverage Initiated at Berenberg Bank

Equities researchers at Berenberg Bank initiated coverage on shares of BioNTech (NASDAQ:BNTX - Get Free Report) in a report issued on Tuesday, Marketbeat Ratings reports. The firm set a "buy" rating and a $130.00 price target on the stock. Berenberg Bank's price objective would indicate a potential upside of 22.18% from the stock's current price.

Several other equities analysts have also recently commented on the company. Hsbc Global Res upgraded BioNTech from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 2nd. The Goldman Sachs Group raised BioNTech from a "neutral" rating to a "buy" rating and raised their price target for the company from $90.00 to $137.00 in a report on Friday, November 8th. HC Wainwright reaffirmed a "buy" rating and set a $150.00 target price on shares of BioNTech in a report on Monday. Evercore ISI raised BioNTech from an "in-line" rating to an "outperform" rating and lifted their target price for the company from $110.00 to $125.00 in a research note on Tuesday. Finally, Morgan Stanley upgraded BioNTech from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $93.00 to $145.00 in a report on Tuesday, September 24th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, BioNTech has an average rating of "Moderate Buy" and an average price target of $138.79.

BioNTech Stock Performance

Shares of NASDAQ BNTX traded up $4.53 during mid-day trading on Tuesday, hitting $106.40. 1,104,105 shares of the company were exchanged, compared to its average volume of 808,831. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $113.68 and a 200-day simple moving average of $97.45. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The firm has a market cap of $25.51 billion, a price-to-earnings ratio of -50.67 and a beta of 0.26.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same period in the previous year, the firm earned $0.73 EPS. The business's revenue for the quarter was up 38.9% compared to the same quarter last year. On average, sell-side analysts forecast that BioNTech will post -3.68 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of institutional investors and hedge funds have recently made changes to their positions in BNTX. Covestor Ltd grew its stake in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company's stock worth $38,000 after purchasing an additional 133 shares during the last quarter. Planning Capital Management Corp raised its stake in BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after buying an additional 450 shares during the last quarter. Blue Trust Inc. increased its stake in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock worth $55,000 after purchasing an additional 388 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company's stock worth $43,000 after buying an additional 252 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of BioNTech by 86.9% during the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company's stock valued at $41,000 after purchasing an additional 238 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.